For some patients with systemic lupus erythematosus, regular repeated treatment with rituximab may prevent disease flare, according to a study from Cassia et al.
Biologics May Prevent Cardiovascular Events in RA Patients
RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.
2020 State Legislative Roundup: The Year That Could Have Been & the Year That Was
The COVID-19 pandemic and response disrupted state legislative sessions and agendas in 2020, leaving many ACR priorities unfulfilled and highlighting the urgent need for vocal rheumatology leaders in Washington, D.C., and state capitols.
Advocacy 101 Teaches Legislative, Advocacy Basics
Bharat Kumar, MD, Advocacy 101 coordinator and Government Affairs Committee member, describes the virtual program designed to educate and empower rheumatology fellows in training, program directors and ARP members to advocate for issues that affect rheumatology practices and patients in advance of the Advocates for Arthritis that will take place virtually in September.
Bloody Important: Atherosclerosis & Thrombotic Disease in Rheumatic Conditions
During the 2020 ACR State-of-the-Art Clinical Symposium, Zoltán Szekanecz, MD, PhD, addressed the risks of vascular disease and how to manage them in patients with rheumatic diseases.
How to Create a Safe Practice & Prep for a COVID-19 Resurgence
For many months, the healthcare world has been significantly affected by the swift and pervasive effects of SARS-CoV-2, which causes COVID-19. The virus has severely affected the delivery of patient care by all providers, including those in hospitals and emergency care settings, who grappled with the response to massive influxes of COVID-19 patients, and those…
The Problem with Peer Review
I should have paid more attention in medical school. If I had, I might have remembered enough about basic pathophysiology to know why everyone was suddenly pulling their patients off of lisinopril. For those of you who need a quick primer: When the pressure in the renal artery drops, the kidney secretes renin. Working together,…
ACR Leaders Discuss Hydroxychloroquine Issues with FDA Commissioner
The conversation with Stephen Hahn, MD, addressed challenges associated with hydroxychloroquine access during the COVID-19 public health emergency and handling patient concerns about potential cardiac side effects.
ACR Convergence 2020 Keynote Speaker to Discuss COVID-19 & a Changing Medical Communications Industry
Editor’s note: Registration for ACR Convergence 2020 is now open. Less than a year after becoming editor in chief of The New England Journal of Medicine (NEJM), Eric Rubin, MD, PhD, found himself in the thick of the COVID-19 pandemic. SARS-CoV-2-related submissions flooded the journal office at an unprecedented pace, making an impact on the…
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 304
- Next Page »